AKBA vs. ESPR, ADCT, MREO, LRMR, TERN, AQST, DNTH, HROW, STTK, and ANRO
Should you be buying Akebia Therapeutics stock or one of its competitors? The main competitors of Akebia Therapeutics include Esperion Therapeutics (ESPR), ADC Therapeutics (ADCT), Mereo BioPharma Group (MREO), Larimar Therapeutics (LRMR), Terns Pharmaceuticals (TERN), Aquestive Therapeutics (AQST), Dianthus Therapeutics (DNTH), Harrow Health (HROW), Shattuck Labs (STTK), and Alto Neuroscience (ANRO). These companies are all part of the "pharmaceutical preparations" industry.
Akebia Therapeutics (NASDAQ:AKBA) and Esperion Therapeutics (NASDAQ:ESPR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk, profitability and community ranking.
Akebia Therapeutics has a net margin of -26.32% compared to Esperion Therapeutics' net margin of -179.87%.
Akebia Therapeutics currently has a consensus price target of $5.00, indicating a potential upside of 167.38%. Esperion Therapeutics has a consensus price target of $9.33, indicating a potential upside of 256.23%. Given Esperion Therapeutics' higher probable upside, analysts clearly believe Esperion Therapeutics is more favorable than Akebia Therapeutics.
In the previous week, Esperion Therapeutics had 14 more articles in the media than Akebia Therapeutics. MarketBeat recorded 30 mentions for Esperion Therapeutics and 16 mentions for Akebia Therapeutics. Akebia Therapeutics' average media sentiment score of 0.43 beat Esperion Therapeutics' score of 0.30 indicating that Akebia Therapeutics is being referred to more favorably in the media.
Esperion Therapeutics received 188 more outperform votes than Akebia Therapeutics when rated by MarketBeat users. Likewise, 69.71% of users gave Esperion Therapeutics an outperform vote while only 64.05% of users gave Akebia Therapeutics an outperform vote.
Akebia Therapeutics has a beta of 0.78, indicating that its stock price is 22% less volatile than the S&P 500. Comparatively, Esperion Therapeutics has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500.
Akebia Therapeutics has higher revenue and earnings than Esperion Therapeutics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Esperion Therapeutics, indicating that it is currently the more affordable of the two stocks.
33.9% of Akebia Therapeutics shares are owned by institutional investors. Comparatively, 47.4% of Esperion Therapeutics shares are owned by institutional investors. 3.8% of Akebia Therapeutics shares are owned by company insiders. Comparatively, 0.6% of Esperion Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
Akebia Therapeutics beats Esperion Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Akebia Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AKBA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Akebia Therapeutics Competitors List
Related Companies and Tools